肝细胞癌药物市场规模、份额、成长分析（按药物类别、治疗类型、治疗类型、给药途径、最终用户、分销管道和地区划分）- 产业预测，2025 年至 2032 年

2023 年全球肝细胞癌药物市场规模为 14 亿美元，预计将从 2024 年的 15.2 亿美元成长到 2032 年的 28.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.3%。

随着患者人口结构的变化、政府在肿瘤学方面的支出增加以及标靶治疗的进步，全球肝细胞癌 (HCC) 治疗市场正在经历显着增长。全球对医疗创新的投资正在加速新疗法的采用，尤其是针对肝癌的精准药物。早期诊断的增加以及免疫疗法和联合治疗的采用不断增加，正在扩大整个医疗保健系统中 HCC 治疗的可用性。精准肿瘤学领域的显着创新，例如生物标记引导治疗和下一代蛋白酪氨酸激酶抑制剂 (TKI)，正在为 HCC 治疗的突破铺平道路。此外，人工智慧驱动的药物发现平台正在促进有前景的新型免疫疗法的快速发展，进一步增强了市场的前景。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

肝细胞癌药物市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概览
• PD-1/PD-L1抑制剂
• 蛋白酪氨酸激酶抑制剂

肝细胞癌药物市场规模（依治疗类型和复合年增长率） (2025-2032)

• 市场概览
• 标靶治疗
• 免疫疗法
• 其他的

肝细胞癌药物市场规模（依治疗类型和复合年增长率） (2025-2032)

• 市场概览
• 药物治疗、手术
• 放射线治疗
• 化疗
• 其他的

肝细胞癌药物市场规模（依给药途径及复合年增长率） (2025-2032)

• 市场概览
• 口服
• 注射
• 其他的

肝细胞癌药物市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 居家护理
• 专科诊所
• 其他的

肝细胞癌药物市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 网路药局
• 零售药局

肝细胞癌药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Exelixis, Inc.（US）
• Merck & Co., Inc.（US）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（US）
• Eli Lilly and Company（US）
• SillaJen, Inc.（South Korea）
• Bayer AG（Germany）
• Janssen Global Services, LLC（US）
• Pfizer Inc.（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Gilead Sciences, Inc.（US）
• GSK plc（UK）
• Takeda Pharmaceutical Company Limited（Japan）
• Amgen Inc.（US）
• Polaris Group（US）
• Hepion Pharmaceuticals, Inc.（US）
• Provectus Biopharmaceuticals, Inc.（US）

结论和建议

Global Hepatocellular Carcinoma Drugs Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.52 billion in 2024 to USD 2.87 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global hepatocellular carcinoma (HCC) drugs market is experiencing significant growth, driven by evolving patient demographics, increased government expenditure on oncology, and advancements in targeted therapies. Worldwide investments in health innovation are accelerating the adoption of new treatments, particularly precision medicine dedicated to liver cancer. The rise of early diagnoses, along with the growing implementation of immunotherapies and combination therapies, is expanding the utilization of HCC medications across healthcare delivery systems. Notable innovations in precision oncology, including biomarker-guided therapies and next-generation tyrosine kinase inhibitors (TKIs), are paving the way for breakthroughs in HCC treatment. Additionally, artificial intelligence-driven drug discovery platforms are facilitating the rapid development of promising new immunotherapies, further enhancing the market's prospects.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatocellular Carcinoma Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatocellular Carcinoma Drugs Market Segments Analysis

Global Hepatocellular Carcinoma Drugs Market is segmented by Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel and region. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors and Tyrosine Kinase Inhibitors. Based on Therapy Type, the market is segmented into Targeted Therapy, Immunotherapy and Others. Based on Treatment Type, the market is segmented into Medication, Surgery, Radiotherapy, Chemotherapy and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hepatocellular Carcinoma Drugs Market

The global hepatocellular carcinoma (HCC) drugs market is largely driven by the rising incidence of HCC globally, largely due to chronic hepatitis B and C infections that are becoming resistant to treatment. Additionally, increasing alcohol consumption and the prevalence of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), which are linked to the growing rates of obesity and diabetes, contribute to this upward trend. With a substantial and expanding patient population requiring effective treatment options, there is a consistent demand for both existing therapies and newly developed drugs to address this pressing health challenge.

Restraints in the Global Hepatocellular Carcinoma Drugs Market

The global hepatocellular carcinoma drugs market faces significant obstacles primarily due to the high costs associated with immunotherapies and targeted treatments, which restrict access for patients, particularly in low- and middle-income nations. Additionally, established markets implement stringent health technology assessment (HTA) policies, such as those from NICE and IQWiG, which require lengthy evaluations before providing reimbursement for expensive therapies. This can further limit patient access and delay the introduction of innovative treatments, despite their proven clinical efficacy, thereby hindering the overall growth and development of the market for hepatocellular carcinoma drugs.

Market Trends of the Global Hepatocellular Carcinoma Drugs Market

The Global Hepatocellular Carcinoma (HCC) drug market is witnessing a significant trend towards the rapid expansion of combination therapies, particularly involving PD-1/PD-L1 inhibitors alongside Tyrosine Kinase Inhibitors (TKIs) and anti-angiogenic agents. Notable combinations, such as Roche's Tecentriq (atezolizumab) with Avastin (bevacizumab), have demonstrated remarkable clinical efficacy, including a 42% reduction in mortality risk as observed in the IMbrave150 trial. This trend is further propelled by accelerated approval processes from regulatory bodies like the FDA and EMA, amplifying market growth potential. As clinical outcomes improve, the demand for effective HCC treatments continues to rise, reshaping the landscape of oncological therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Hepatocellular Carcinoma Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• PD-1/PD-L1 Inhibitors
• Tyrosine Kinase Inhibitors

Global Hepatocellular Carcinoma Drugs Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Targeted Therapy
• Immunotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Medication, Surgery
• Radiotherapy
• Chemotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Others

Global Hepatocellular Carcinoma Drugs Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Hepatocellular Carcinoma Drugs Market Size & CAGR (2025-2032)

• North America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SillaJen, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Global Services, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Polaris Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Provectus Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations